dicycloverine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
spasmolytics with a papaverine-like action 868 77-19-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • dicymine
  • dicycloverine hydrochloride
  • dicycloverine
  • dicyclomine
  • dicycloverin
  • dicyclomine hydrochloride
  • dicyclomine HCl
A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.
  • Molecular weight: 309.49
  • Formula: C19H35NO2
  • CLOGP: 6.14
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 29.54
  • ALOGS: -4.98
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
80 mg O
80 mg P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 4.30 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
May 11, 1950 FDA FOREST LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cholecystitis chronic 195.68 12.24 97 22171 10402 46653392
Biliary dyskinesia 104.60 12.24 42 22226 2731 46661063
Abdominal pain 96.51 12.24 284 21984 229747 46434047
Irritable bowel syndrome 93.08 12.24 71 22197 16444 46647350
Gallbladder disorder 83.07 12.24 68 22200 17430 46646364
Anxiety 60.93 12.24 208 22060 181749 46482045
Abdominal pain upper 46.77 12.24 164 22104 145141 46518653
Diarrhoea 46.52 12.24 438 21830 559164 46104630
Rheumatoid arthritis 43.21 12.24 31 22237 240184 46423610
Gallbladder injury 35.78 12.24 16 22252 1358 46662436
Injury 34.13 12.24 69 22199 43958 46619836
Pain 33.13 12.24 360 21908 476588 46187206
Cholelithiasis 32.86 12.24 63 22205 38618 46625176
Depression 32.00 12.24 163 22105 169941 46493853
Colitis ulcerative 29.09 12.24 39 22229 17693 46646101
Nausea 28.68 12.24 473 21795 686981 45976813
Gallbladder hypofunction 26.94 12.24 10 22258 525 46663269
Biliary colic 26.49 12.24 18 22250 3480 46660314
Maternal exposure during pregnancy 26.47 12.24 8 22260 102541 46561253
Treatment failure 26.42 12.24 6 22262 93081 46570713
Contraindicated product administered 25.14 12.24 4 22264 79943 46583851
Emotional distress 24.85 12.24 49 22219 30658 46633136
Drug ineffective 24.32 12.24 207 22061 677631 45986163
Therapy partial responder 23.92 12.24 19 22249 4663 46659131
Drug interaction 22.46 12.24 39 22229 203055 46460739
Pre-existing condition improved 21.98 12.24 21 22247 6591 46657203
Thrombocytopenia 21.87 12.24 17 22251 126564 46537230
Abdominal distension 21.20 12.24 80 22188 73271 46590523
Constipation 20.66 12.24 148 22120 173949 46489845
Neutropenia 20.32 12.24 23 22245 143181 46520613
Flatulence 19.75 12.24 43 22225 28835 46634959
Scleritis 19.74 12.24 14 22254 2898 46660896
Poor peripheral circulation 19.25 12.24 14 22254 3013 46660781
Migraine 18.30 12.24 74 22194 69952 46593842
Hyponatraemia 18.29 12.24 13 22255 101319 46562475
Cholecystectomy 18.17 12.24 22 22246 9020 46654774
Pancytopenia 18.04 12.24 9 22259 85049 46578745
Surgery 17.60 12.24 41 22227 28744 46635050
Hypoaesthesia 17.08 12.24 106 22162 118763 46545031
Psychological trauma 17.05 12.24 9 22259 1099 46662695
Diverticulitis 16.96 12.24 44 22224 32995 46630799
Intestinal obstruction 16.89 12.24 38 22230 26037 46637757
Clostridium difficile infection 16.73 12.24 37 22231 25066 46638728
Suicidal ideation 16.71 12.24 62 22206 56320 46607474
Small intestinal obstruction 15.82 12.24 28 22240 16144 46647650
Death 15.59 12.24 95 22173 335453 46328341
Synovitis 15.33 12.24 5 22263 61070 46602724
Impaired gastric emptying 15.19 12.24 19 22249 8053 46655741
Drug intolerance 14.70 12.24 30 22238 147019 46516775
Pancreatitis 14.66 12.24 50 22218 43577 46620217
Chest pain 14.51 12.24 138 22130 176186 46487608
Intestinal mucosal hypertrophy 14.43 12.24 5 22263 215 46663579
Interstitial lung disease 14.30 12.24 4 22264 53945 46609849
Cholesterosis 14.26 12.24 6 22262 439 46663355
Muscle spasms 14.21 12.24 104 22164 123009 46540785
Weight decreased 13.57 12.24 157 22111 210692 46453102
Tonsillitis fungal 13.05 12.24 3 22265 27 46663767
C-reactive protein increased 12.73 12.24 6 22262 58584 46605210
Joint swelling 12.62 12.24 39 22229 166034 46497760
Palpitations 12.48 12.24 83 22185 95176 46568618

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Diarrhoea 36.34 15.57 133 5039 333970 29613336
Irritable bowel syndrome 36.26 15.57 15 5157 2937 29944369
Abdominal pain 30.27 15.57 70 5102 135584 29811722
Colitis ulcerative 24.17 15.57 20 5152 14414 29932892
Apathy 18.03 15.57 12 5160 6220 29941086
Rectourethral fistula 16.09 15.57 3 5169 27 29947279
Abdominal pain upper 15.84 15.57 34 5138 62517 29884789

Pharmacologic Action:

SourceCodeDescription
ATC A03AA07 ALIMENTARY TRACT AND METABOLISM
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
Synthetic anticholinergics, esters with tertiary amino group
FDA MoA N0000175370 Cholinergic Antagonists
FDA EPC N0000175574 Anticholinergic
CHEBI has role CHEBI:48876 antimuskarinika
CHEBI has role CHEBI:50370 parasympatholytics
CHEBI has role CHEBI:53784 antispasmodics
MeSH PA D018678 Cholinergic Agents
MeSH PA D018680 Cholinergic Antagonists
MeSH PA D018727 Muscarinic Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D010276 Parasympatholytics
MeSH PA D018373 Peripheral Nervous System Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Irritable bowel syndrome indication 10743008 DOID:9778
Calculus in biliary tract off-label use 266474003
Brain damage contraindication 2470005
Tachyarrhythmia contraindication 6285003
Suicidal thoughts contraindication 6471006
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Hyperammonemia contraindication 9360008
Hepatic encephalopathy contraindication 13920009 DOID:13413
Severe chronic ulcerative colitis contraindication 14311001
Toxic megacolon contraindication 28536002 DOID:1770
Atony of colon contraindication 29479008
Hyperthyroidism contraindication 34486009 DOID:7998
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Complete trisomy 21 syndrome contraindication 41040004 DOID:14250
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Paralytic ileus contraindication 55525008 DOID:8442
Peptic reflux disease contraindication 57643001
Hepatic failure contraindication 59927004
Ulcerative colitis contraindication 64766004 DOID:8577
Poisoning by phenobarbital contraindication 64921004
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Substance abuse contraindication 66214007
Hepatic coma contraindication 72836002 DOID:12550
Sleep apnea contraindication 73430006 DOID:0050847
Spastic paralysis contraindication 78403003
Disturbance of salivary secretion contraindication 78948009
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Gastrointestinal obstruction contraindication 126765001
Autonomic dysreflexia contraindication 129618003
Bleeding contraindication 131148009
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Benign prostatic hyperplasia contraindication 266569009
Dyspnea contraindication 267036007
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Angle-closure glaucoma contraindication 392291006 DOID:13550
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Porphyria contraindication 418470004
Fever greater than 100.4 Fahrenheit contraindication 426000000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.41 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Muscarinic acetylcholine receptor M3 GPCR ANTAGONIST Ki 9.03 DRUG MATRIX CHEMBL
Muscarinic acetylcholine receptor M1 GPCR ANTAGONIST Ki 9.08 DRUG MATRIX CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 4.77 DRUG MATRIX
5-hydroxytryptamine receptor 2A GPCR Ki 7.16 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 6.08 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.61 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 5.85 DRUG MATRIX
D(3) dopamine receptor GPCR Ki 6.39 DRUG MATRIX
Histamine H2 receptor GPCR Ki 5.80 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 9.39 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 8.77 DRUG MATRIX
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 4.55 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR ANTAGONIST Ki 6.60 IUPHAR
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 8.69 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor IC50 6.33 DRUG MATRIX
SMR1-alpha2 Unclassified Ki 6.54 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 8.61 CHEMBL
Muscarinic acetylcholine receptor M2 GPCR Ki 7.33 CHEMBL

External reference:

IDSource
4017870 VUID
N0000179550 NUI
D00717 KEGG_DRUG
67-92-5 SECONDARY_CAS_RN
4017870 VANDF
4019716 VANDF
C0012125 UMLSCUI
CHEBI:4514 CHEBI
CHEMBL1123 ChEMBL_ID
CHEMBL1200479 ChEMBL_ID
DB00804 DRUGBANK_ID
D004025 MESH_DESCRIPTOR_UI
3042 PUBCHEM_CID
355 IUPHAR_LIGAND_ID
619 INN_ID
4KV4X8IF6V UNII
152021 RXNORM
158 MMSL
4587 MMSL
d00999 MMSL
001758 NDDF
004711 NDDF
372732007 SNOMEDCT_US
41493007 SNOMEDCT_US
71043005 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0054-0622 SOLUTION 10 mg ORAL ANDA 24 sections
Dicyclomine HUMAN PRESCRIPTION DRUG LABEL 1 0143-1227 TABLET 20 mg ORAL ANDA 26 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0143-3126 CAPSULE 10 mg ORAL ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1610 CAPSULE 10 mg ORAL ANDA 27 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0378-1620 TABLET 20 mg ORAL ANDA 27 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0440-7384 CAPSULE 10 mg ORAL ANDA 26 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0517-1980 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 24 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-0586 CAPSULE 10 mg ORAL ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0527-1282 TABLET 20 mg ORAL ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0794 CAPSULE 10 mg ORAL ANDA 25 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0591-0795 TABLET 20 mg ORAL ANDA 25 sections
dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0603-1161 SOLUTION 10 mg ORAL ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0641-6173 INJECTION 10 mg INTRAMUSCULAR ANDA 25 sections
Dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6969 CAPSULE 10 mg ORAL ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6987 CAPSULE 10 mg ORAL ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0904-6988 TABLET 20 mg ORAL ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10135-520 CAPSULE 10 mg ORAL ANDA 25 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 10544-560 TABLET 20 mg ORAL ANDA 26 sections
Dicyclomine HUMAN PRESCRIPTION DRUG LABEL 1 10544-597 TABLET 20 mg ORAL ANDA 20 sections
Dicyclomine HCl HUMAN PRESCRIPTION DRUG LABEL 1 14789-010 INJECTION 10 mg INTRAMUSCULAR ANDA 25 sections
dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16590-077 CAPSULE 10 mg ORAL ANDA 11 sections
DICYCLOMINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-324 TABLET 20 mg ORAL ANDA 8 sections
Dicyclomine HUMAN PRESCRIPTION DRUG LABEL 1 17478-015 INJECTION 20 mg INTRAMUSCULAR ANDA 25 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-0623 SOLUTION 10 mg ORAL ANDA 24 sections
dicyclomine hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 17856-1161 SOLUTION 10 mg ORAL ANDA 20 sections
Dicyclomine HUMAN PRESCRIPTION DRUG LABEL 1 21695-218 CAPSULE 10 mg ORAL ANDA 22 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 21695-219 TABLET 20 mg ORAL ANDA 20 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 24201-585 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 24 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 31722-963 INJECTION, SOLUTION 20 mg INTRAMUSCULAR ANDA 26 sections
Dicyclomine Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 33261-163 TABLET 20 mg ORAL ANDA 26 sections